SCHEMBL4347177

SCHEMBL4347177

O=C1N=C(N2CCOCC2)S/C1=C\c1cccc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.62
ALDH1A1 P00352 9/20 0.61
CYP1A2 P05177 2/20 0.61
CYP2C19 P33261 2/20 0.61
RAB9A P51151 6/20 0.58
NPC1 O15118 3/20 0.58
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
HTT P42858 3/20 0.56
SENP1 Q9P0U3 1/20 0.56
POLB P06746 2/20 0.55
GLA P06280 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
HPGD P15428 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
LMNA P02545 1/20 0.53
THRB P10828 1/20 0.53
HCRTR1 O43613 1/20 0.53
KDM4E B2RXH2 1/20 0.53
GAA P10253 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4347179 1.00 MAPT (0.62) MAPTALDH1A1CYP1A2CYP2C19RAB9A
SCHEMBL4351281 0.88 SENP1 (0.71) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL4351282 0.88 SENP1 (0.71) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL4350166 0.87 NPC1 (0.59) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL4350162 0.87 NPC1 (0.59) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL4350532 0.86 MAPT (0.60) MAPTALDH1A1CYP1A2CYP2C19RAB9A
SCHEMBL4350529 0.86 MAPT (0.60) MAPTALDH1A1CYP1A2CYP2C19RAB9A
SCHEMBL4359797 0.86 NPC1 (0.58) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL4359795 0.86 NPC1 (0.58) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL3431086 0.83 SENP1 (0.78) MAPTALDH1A1CYP1A2CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885ALDH1A1 284/4885CYP1A2 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.